Table 2 Characteristics of Included Studies
Study | Co-interventions | Transfusion threshold | Anti-platelet use |
|---|---|---|---|
Isetta et al. [25] | PO CS - re-transfusion of SMB | Hct<20% during CPB Hct<25% 4 hrs post CPB Hct<27% post-op. | NR |
Blauhut et al. [27] | NR | Hct<30% post-op. | Excluded pts. pre-operatively treated with ASA + NSAIDs |
Penta de Peppo et al. [20] | IO CS + IO & PO re-transfusion of SMB | Post-op. non-monitored pts. Hb<7.0 g/dL Monitored pts. Hb<8.5 g/dL | Discontinued NSAIDs 24 hrs before Sx. |
Corbeau et al. [23] | NR | Hct<20% during CPB Hct<25% at the end of surgery Hct<30 post extubation | Anti-platelet aggregation drugs ceased 10 days pre-operatively |
Pugh et al. [22] | IO CS + ANH (1 unit of WB collected pre-CPB then re-transfused post CPB) | Hct<20% during CPB Hct<30% off CPB | Aspirin use within 10 days of the operation: LD APR = 67%, TXA = 91%, Control = 78% |
Speekenbrink et al. [21] | NR | NR | Aspirin discontinued 2–4 days before Sx. |
Menichetti et al. [24] | NR | Hct<30% post-operatively | Excluded pts. who had taken ASA or DIP until 2 weeks pre-op. |
Pinosky et al. [33] | NR | Hct<20% + surgeon preference | Pre-operative aspirin use: TXA = 25%, EACA = 40%, Placebo = 42% |
Mongan et al. [31] | NR | Hb<6.0 g/dL during CPB Hb<8.0 g/dL off CPB | Pre-operative aspirin use: HD APR = 44%, TXA = 53% |
Hardy et al. [26] | IO CS & Re-infusion of SMB were not used | Hb<7.0 g/dL during CPB Hb<8.0 g/dL off CPB | NR |
Eberle et al. [29] | IO & PO CS used | Hct<27% - post-operative + accompanied by signs & symptoms of hypovolemia | Intra-operative IV ASA: HD APR = 5.0%, EACA = 15% |
Misfeld et al. [30] | NR | Hb<8.0 g/dL | Excluded pts. receiving ASA treatment within 5 days of Sx. |
Casati et al. [28] | IO CS used + PAD | Hb<6.0 g/dL during CPB Hb<8.0 g/dL off CPB + clinical condition | Pts. receiving ASA treatment within 5 days of Sx.: HD APR = 37.8%, TXA = 40.9%, EACA = 35.3% |
Bernet et al. [34] | PO CS | Hct<25% PO | All pts. were treated with 100 mg ASA daily until Sx. |
Nuttall et al. [32] | PAD not used | Hb<7.0 g/dL during CPB | Excluded pts. taking ASA daily (≥325 mg) before Sx. |
Maineri et al. [38] | IO CS + PO re-infusion of SMB | Hct<30% IO Hct<28% PO | NR |
Wong et al. [37] | IO CS + PO re-infusion of SMB | Hb<7.0 g/dL IO Hb<8.0 g/dL PO | Excluded pts. receiving ASA treatment within 5 days of Sx. |
Casati et al. [35] | IO CS used | Hb<6.0 g/dL during CPB Hb<8.0 g/dL PO | Pts. receiving ASA treatment before Sx.: HD APR = 17.8%, TXA = 18.8% |
Greilich et al. [36] | IO CS used PO SMB was not used | Hb<8.0 g/dL | Pts. receiving ASA treatment before Sx.: HD APR = 88%, EACA = 90%, Placebo = 79% |
Ray et al. [6] | NR | NR | ASA within 10 days before Sx.: LD APR = 22.4%, EACA = 33.3% |